Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep-Oct;80(5):535-540.
doi: 10.1016/j.mjafi.2022.12.011. Epub 2023 Feb 3.

532 nm versus 810 nm subthreshold micropulse laser in treatment of non-resolving central serous chorioretinopathy: A randomized controlled trial

Vikas Ambiya  1 , Ashok Kumar  2 , Sankalp Seth  3 , Pradeep Kumar  4 , Avadesh Oli  5
Affiliations

532 nm versus 810 nm subthreshold micropulse laser in treatment of non-resolving central serous chorioretinopathy: A randomized controlled trial

Vikas Ambiya et al. Med J Armed Forces India. 2024 Sep-Oct.

Abstract

Background: The relative efficacy of 532 nm subthreshold micropulse laser in comparison to the 810 nm subthreshold micropulse laser, in the treatment of central serous chorioretinopathy is not known.

Methods: This randomized controlled trial included 99 eyes each in groups A and B. Key inclusion criteria were: (i) vision loss for minimum three months due to persistent central serous chorioretinopathy; (ii) focal leaks (upto two leaks) on fundus fluorescein angiography. Key exclusion criteria were: (i) history of prior treatment for central serous chorioretinopathy; (ii) absence of any leak/ presence of diffuse leaks/ >2 leaks on fundus fluorescein angiography; (iii) chronic central serous chorioretinopathy. All eyes were treated with subthreshold micropulse laser (group A: 532 nm green laser; group B: 810 nm diode laser). Best-corrected visual acuity, autofluorescence, spectral domain optical coherence tomography, and fundus fluorescein angiography, were evaluated at baseline and at 1, 3, and 6 months. Laser was repeated in nor-responders at 3 months.

Results: There was a statistically significant improvement in BCVA in both groups six months post laser. Between the two groups, a comparable proportion of eyes showed complete resolution of subretinal fluid at one month, three months and at six months. No adverse effect of laser was observed in either group.

Conclusion: Both 532 nm STMP laser and 810 nm STMP laser have comparable structural and functional outcomes in the treatment of non-resolving CSC. There are no adverse effects related to either of the two wavelengths.

Keywords: Central serous chorioretinopathy; Sub-retinal fluid; Subthreshold micropulse laser.

PubMed Disclaimer

Conflict of interest statement

The authors have none to declare.

Figures

Fig. 1
Fig. 1
Best-corrected visual acuity in eyes with central serous chorioretinopathy at baseline and during follow-up after treatment with 532 nm versus 810 nm subthreshold micropulse laser.
Fig. 2
Fig. 2
Height of subfoveal neurosensory detachment in eyes with central serous chorioretinopathy at baseline and during follow-up after treatment with 532 nm versus 810 nm subthreshold micropulse laser.
Fig. 3
Fig. 3
Percentage of eyes showing complete resolution of subretinal fluid during follow-up after treatment with 532 nm versus 810 nm subthreshold micropulse laser.
Fig. 4
Fig. 4
Central macular thickness in eyes with central serous chorioretinopathy at baseline and during follow-up after treatment with 532 nm versus 810 nm subthreshold micropulse laser.
Fig. 5
Fig. 5
Proportion of eyes needing repeat laser after 3 months of follow-up post treatment with 532 nm versus 810 nm subthreshold micropulse laser.
See this image and copyright information in PMC

References

    1. Ulbig M.R., Arden G.B., Hamilton A.P. Color contrast sensitivity and pattern electroretinographic findings after diode and argon laser photocoagulation in diabetic retinopathy. Am J Ophthalmol. 1994;117(5):583–588. - PubMed
    1. Lewen R.M. Subretinal neovascularization complicating laser photocoagulation of diabetic maculopathy. Ophthal Surg Lasers Imaging Retina. 1988;19(10):734–737. - PubMed
    1. Smith C.W., Guyer D.R., D'Amico D.J. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol. 1992;113(6):652–656. - PubMed
    1. Seiberth V., Alexandridis E., Feng W. Function of the diabetic retina after panretinal argon laser coagulation. Graefes Arch Clin Exp Ophthalmol. 1987;225(6):385–390. - PubMed
    1. Pearson A., Tanner V., Keightley S., Casswell A. What effect does laser photocoagulation have on driving visual fields in diabetics? Eye (Lond). 1998;12(1):64–68. - PubMed

LinkOut - more resources